Media Contact
Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday:
- Andrea Greif
Senior Director, Communications
(914) 821-8958
andrea.greif@lls.org
More Progress on LLS-Supported CAR T-cell Immunotherapy
Rye Brook, N.Y. (May 2, 2018) – The latest approval of a game-changing personalized cancer therapy on Tuesday is further proof of the promise of immunotherapy, an approach that The Leukemia & Lymphoma Society (LLS) supported early on and which holds great promise for blood cancer patients, as well as for patients with other types of cancers. The U.S. Food and Drug Administration (FDA) granted ti...
Leukemia Patient’s Legacy Helps Drive Innovative Cancer Clinical Trial
Rye Brook, NY (March 21, 2018) - Turning sorrow into action, The Harry T. Mangurian Jr. Foundation, whose namesake died from acute myeloid leukemia (AML), continues to fuel The Leukemia & Lymphoma Society’s (LLS) ambitious attack on this deadly blood cancer. Specifically, with the Foundation’s support, LLS is leading a paradigm shift to treating cancers with a precision medicine approach – the right d...
When Competition and Philanthropy Go Hand-in-Hand
Rye Brook, NY - March 15, 2018 – One of the greatest competitors of all time, Michael Jordan, once said, “Talent wins games, but teamwork and intelligence win championships.” Today, The Leukemia & Lymphoma Society® (LLS) officially kicks off the 29th annual competitive fundraising campaign, Man & Woman of the Year®. In 80 communities across the country, a select group of individuals and their cam...
The Time is Now for More Women in Science
View multimedia release here. Rye Brook, N.Y. (March 13, 2018) – As breakthroughs in cancer treatments are occurring at an ever increasing rate, The Leukemia & Lymphoma Society (LLS) is shining a spotlight on the women in science who are helping to lead these advances. Through its significant investment in cancer research – more than $1.2 billion since its founding nearly 70 years ago – LL...
LLS Announces New Research Program for Deadly Blood Cancer
Rye Brook, NY – Jan. 8, 2018 - The Leukemia & Lymphoma Society (LLS), the world’s largest voluntary health organization dedicated to fighting blood cancer, announced today new funding for research programs in mantle cell lymphoma (MCL) treatment through a generous donation from The Sarah Cannon Fund at The HCA Foundation. Among the 72,000 new cases per year of non-Hodgkin lymphomas (NHLs), approximately 4,...
Burlington Stores Raises More Than $32 Million For LLS
Rye Brook, NY (December 12, 2017) – For the 16th year, Burlington Stores and The Leukemia & Lymphoma Society’s (LLS) Light The Night campaign united to shine a light on the urgent need to fund blood cancer research and help patients access lifesaving treatments and cures. From September 17 through December 9, Burlington store locations across the country encouraged customers to donate $1 or more at checkout t...
LLS Achieves New Milestones in Offensive Against Deadly Blood Cancer AML
Rye Brook, NY (December 6, 2017) – The Leukemia & Lymphoma Society® (LLS) continues its assault against acute myeloid leukemia (AML), a deadly blood cancer that kills more than 10,000 Americans a year. LLS today announced its groundbreaking precision medicine Beat AML® Master Clinical Trial is seeing a rapid increase in patients enrolled as more leading cancer centers and biopharmaceutical companies...
John Quinones Appears with Blood Cancer Survivors in PSA for LLS
Rye Brook, NY, (December 7, 2017) --“If you had a chance to support research that is saving lives…What would you do?” asks John Quinones in a new public service announcement for The Leukemia & Lymphoma Society, titled “I Live.” The ABC News correspondent and host of the popular television series, What Would You Do? is featured in the compelling segments, joined by a group of children and one adult who a...